The prognostic influence of serum neuron specific enolase in small cell lung cancer

Jørgensen, Lone; Østerlind, Kell; Hansen, Heine H.; Eh, Cooper

doi:10.1038/bjc.1988.313

Cited by 53 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The additional finding of a shorter remission duration in patients whose levels subsequently rose again despite continued treatment may have considerable significance for the selection of therapy and should be prospectively tested in larger numbers of patients. The prognostic significance of NSE level has only been tested in multivariate analysis in one previous study (Jorgensen et al, 1988), whose results are confirmed here. Neurone-specific enolase is the best single predictor of both remission duration and overall survival in this series of patients and although closely correlated with the more widely used LDH it carries independent power even when the latter is included in regression analysis.…”

Section: Resultssupporting

confidence: 66%

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer

1994

Lung Cancer

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 66%

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer

1994

Lung Cancer

View full text Add to dashboard Cite

“…Several groups have shown that serum NSE is elevated in the majority of patients with extensive SCLC and a significant proportion of those with limited disease (Carney et al, 1982;Johnson et al, 1984;Akoun et al, 1985;Cooper et al, 1985;Esscher et al, 1985). Despite reports that NSE levels are consistently higher in extensive than limited stage SCLC, data on the prognostic value of NSE are limited (Akoun et al, 1985;J0rgensen et al, 1988).…”

mentioning

confidence: 99%

Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance?

Harding

McAllister²,

Hulks³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Pretreatment serum levels of neurone specific enolase (NSE) were measured in patients with small cell lung cancer (SCLC). Median values were significantly higher in patients with extensive compared with limited stage disease (48 ng ml-1 v. 17 ng ml-1: P less than 0.001). Serial NSE levels paralleled the clinical response to treatment. In 37 patients with limited SCLC, receiving identical chemotherapy, the pretreatment NSE level was of prognostic significance: with an approximate reduction in median survival of 10% for each 5 ng ml-1 incremental rise in NSE (P = 0.004).

show abstract

“…Among these three tumor markers, NSE is considered to be the most sensitive to SCLC; this has been confirmed by numerous studies since Carney et al (13) first proposed NSE as a tumor marker for SCLC. Serum levels of NSE are elevated in 40-45% of patients with LD and in 85-98% of patients with ED (14). Bonner et al (15) reported that pretreatment serum NSE levels may reflect the tumor burden and predict survival, and that higher NSE level indicate a worse prognosis, suggesting …”

Section: A B a B A B Discussionmentioning

confidence: 99%

Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer

Shi

Meng

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the association between serum tumor markers and the metabolic tumor volume (MTV) or total lesion glycolysis (TLG), as determined by fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET/CT) in patients with recurrent small cell lung cancer (SCLC). Data from 21 patients with recurrent SCLC were collected. The levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21-1 were measured at the time of the 18 F-FDG PET/CT examination. The MTV and TLG of all lesions were calculated. Pearson correlation analyses were used to estimate the correlations between NSE level and PET findings. Pearson correlation analyses showed that NSE was the only tumor marker to have a strong correlation with MTV or TLG (r=0.787, P<0.001; r=0.866, P<0.001, respectively). In patients with a normal NSE level, no correlation was found between NSE and MTV or TLG (r=0.018, P=0.958; r=-0.003, P=0.92, respectively), but a significant correlation was found in patients with an abnormal NSE level (r=0.789, P<0.01; r=0.872, P=0.01, respectively). Therefore, TLG and MTV may serve as sensitive markers of tumor burden in patients with recurrent SCLC, with TLG showing greater sensitivity. In patients with an abnormal NSE level, a higher NSE level indicates greater MTV and TLG.

show abstract

The prognostic influence of serum neuron specific enolase in small cell lung cancer

Cited by 53 publications

References 11 publications

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer

Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance?

Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer

Contact Info

Product

Resources

About